

Original Article



Lactobacillus plantarum-derived Extracellular Vesicles Protect Atopic Dermatitis Induced by Staphylococcus aureus-derived Extracellular Vesicles

Min-Hye Kim ,^{1*} Seng Jin Choi,^{2,+} Hyun-Il Choi,^{3,+} Jun-Pyo Choi,⁴ Han-Ki Park,⁵ Eun Kyoung Kim,⁶ Min-Jeong Kim,⁷ Byoung Seok Moon,⁷ Taek-ki Min,⁸ Mina Rho,⁹ Young-Joo Cho,¹ Sanghwa Yang,⁶ Yoon-Keun Kim,⁶ You-Young Kim,¹⁰ Bok Yang Pyun^{8*}

OPEN ACCESS

Received: Jan 16, 2018

Revised: Mar 29, 2018

Accepted: Apr 3, 2018

Correspondence to

Bok Yang Pyun, MD, PhD

Pediatric Allergy and Respiratory Center,
Department of Pediatrics, Soonchunhyang
University Seoul Hospital, Soonchunhyang
University College of Medicine, 59
Daesagwan-ro, Yongsan-gu, Seoul 04401,
Korea.

Tel: +82-2-709-9339

Fax: +82-2-794-5471

E-mail: bypyun@schmc.ac.kr

Min-Hye Kim, MD, PhD

Department of Internal Medicine, Ewha
Womans University College of Medicine,
1071 Anyangcheon-ro, Yangcheon-gu,
Seoul 07985, Korea.

Tel: +82-2-2650-6018

Fax: +82-2-2655-2076

E-mail: mineyang81@ewha.ac.kr

*Seng Jin Choi and Hyun-Il Choi contributed
equally to this work as first authors.

Copyright © 2018 The Korean Academy of
Asthma, Allergy and Clinical Immunology ·
The Korean Academy of Pediatric Allergy and
Respiratory Disease

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

¹Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea

²Research Institute, AEON Medix, Inc., Pohang, Korea

³Department of Life Science, Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, Korea

⁴Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea

⁵Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea

⁶Institute of MD Healthcare, Inc., Seoul, Korea

⁷CJ R&D Center, CJ CheilJedang Corporation, Suwon, Korea

⁸Pediatric Allergy and Respiratory Center, Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea

⁹Department of Computer Science and Engineering, Hanyang University, Seoul, Korea


¹⁰Department of Internal Medicine, National Medical Center, Seoul, Korea

ABSTRACT

Purpose: The microbial environment is an important factor that contributes to the pathogenesis of atopic dermatitis (AD). Recently, it was revealed that not only bacteria itself but also extracellular vesicles (EVs) secreted from bacteria affect the allergic inflammation process. However, almost all research carried out so far was related to local microorganisms, not the systemic microbial distribution. We aimed to compare the bacterial EV composition between AD patients and healthy subjects and to experimentally find out the beneficial effect of some bacterial EV composition.

Methods: Twenty-seven AD patients and 6 healthy control subjects were enrolled. After urine and serum were obtained, EVs were prepared from samples. Metagenomic analysis of 16S ribosomal DNA extracted from the EVs was performed, and bacteria showing the greatest difference between controls and patients were identified. *In vitro* and *in vivo* therapeutic effects of significant bacterial EV were evaluated with keratinocytes and with *Staphylococcus aureus*-induced mouse AD models, respectively.

Results: The proportions of *Lactococcus*, *Leuconostoc* and *Lactobacillus* EVs were significantly higher and those of *Alicyclobacillus* and *Propionibacterium* were lower in the control group than in the AD patient group. Therefore, lactic acid bacteria were considered to be important ones that contribute to the difference between the patient and control groups. *In vitro*, interleukin (IL)-6 from keratinocytes and macrophages decreased and cell viability was restored with *Lactobacillus plantarum*-derived EV treatment prior to *S. aureus* EV treatment.

ORCID iDsMin-Hye Kim <https://orcid.org/0000-0002-1775-3733>**Disclosure**

There are no financial or other issues that might lead to conflict of interest.

In *S. aureus*-induced mouse AD models, *L. plantarum*-derived EV administration reduced epidermal thickening and the IL-4 level.

Conclusions: We suggested the protective role of lactic acid bacteria in AD based on metagenomic analysis. Experimental findings further suggest that *L. plantarum*-derived EV could help prevent skin inflammation.

Keywords: Atopic dermatitis; *Lactobacillus*; microbiome; metagenomics; probiotics

INTRODUCTION

Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterized by itching and xerosis.¹ The prevalence of AD is increasing in developed countries, with rates of 15% to 30% in children and 2% to 10% in adults.²⁻⁴ Epidemiological studies conducted in Korea have also indicated a similar prevalence and an increasing trend for AD.^{5,6} The pathogenesis of AD principally involves systemic and local factors. Systemically, AD is a cutaneous manifestation of a systemic disorder that is accompanied by other allergic disease, such as asthma and allergic rhinitis. Increased blood eosinophil, serum immunoglobulin E (IgE) and deviated systemic Th2 immune responses are characteristics of these systemic disorders.^{7,8} Locally, skin barrier dysfunction, immunologic triggers (allergen and microbial infection) and decreased skin innate immune response are included in the pathogenesis of AD.⁷ AD is likely to occur due to the interactions between systemic and local pathogenic factors.

The collective microbial community has been implicated in AD. Previous work showed that microorganisms affect systemic dysregulation of the innate and acquired immune systems. To the best of our knowledge, no study has comprehensively analyzed systemic microbiome factors. Identifying microorganisms in the blood or urine was considered to be futile, since these sites should be sterile; however, bacterial extracellular vesicles (EVs) have been observed in the blood and other organ systems and are known to contribute to the inflammation process.⁹ EVs are nanometer-sized vesicles derived from archaea, bacteria and eukaryotic cells that enclose cell components including proteins, nucleic acids and lipids, which have been implicated as having a physiological or pathological key role in cell communication.^{10,11} Analysis of bacterial EV in the blood or urine can be exploited to study systemic bacterial conditions.¹²

The lack of studies concerning the overall microbiome has precluded a deep understanding of the effect of bacteria. To understand the complex relationship between human health and bacteria, an approach that is more sophisticated and comprehensive than the culture method is needed.¹³ Metagenomic analysis is not burdened by culture-related limitations because it analyzes bacterial DNA collected directly from the environment regardless of cell viability.^{13,14}

In the present study, we evaluated the systemic bacterial EV composition using metagenomic analysis of bacterial DNA in the urine of AD patients and normal controls. The goal was to identify bacteria contributing systemically to AD, to characterize changes in bacterial composition according to AD treatment and to elucidate the effect of EV from beneficial bacteria through *in vitro* and *in vivo* examinations.

MATERIALS AND METHODS

Study subjects

Patients visiting the Pediatric Allergy and Respiratory Center of Soonchunhyang University Hospital who had aggravated AD according to the Hanifin and Rajka AD diagnostic criteria¹⁵ were enrolled. Patients were excluded if they had other skin diseases, or had received topical, oral or injectable antibiotics within the previous 14 days. Wet dressing, topical corticosteroids and antibiotics were used to treat AD aggravation in all patients, and 66.7% and 18.5% of patients were treated with topical calcineurin inhibitors and systemic corticosteroids, respectively. Normal control children who were recruited had no skin diseases including AD and did not have any other allergic or significant underlying diseases. They were recruited from children who visited the Pediatric Department of Soonchunhyang University Hospital for vaccination and had not used probiotics and systemic antibiotics within 14 days. All participants were less than 17 years of age. Blood and urine were collected from the subjects. Participants and their parents provided informed consent. The study was approved by the Ethics Committee of Soonchunhyang University Hospital (approval number 2013-061).

Laboratory tests and measurement of AD severity

White blood cells and eosinophil count were measured in AD patients. The levels of total IgE, specific IgE and eosinophil cationic protein (ECP) were measured using ImmunoCAP testing according to the manufacturer's instructions (Phadia AB, Uppsala, Sweden). Laboratory tests were not performed in normal controls. AD severity was measured by the SCORing of Atopic Dermatitis (SCORAD) index¹⁶ by the same pediatric allergist to avoid inter-observer bias.

EV preparation from urine and serum, and DNA isolation

Multiple ultracentrifugation and purification processes were applied to isolate EVs, as described in a previous study.¹⁷ DNA was extracted using a commercial kit (Bioneer, Daejeon, Korea), and the quality and quantity of DNA were determined using spectrophotometry (NanoDrop Instruments, Wilmington, DE, USA).

Emulsion-based polymerase chain reaction (emPCR) and next-generation sequence analysis

After each clone was polymerase chain reaction (PCR)-amplified, the V1 to V3 regions were amplified using a FastStart High Fidelity PCR System (Roche Diagnostics GmbH, Mannheim, Germany) with a 16s rRNA gene fusion primer (27F-GAGTTTGATCMTGGCTCAG and 518R-WTTACCGCGGCTGCTGG). A GS-FLX plus emPCR Kit (454 Life Sciences, Branford, CT, USA) and Tissue Lyser II (Qiagen, Germantown, MD, USA) were used to make micro-reactors containing amplified compounds and beads. After emPCR amplification, the amplicon was purified using an AMPure Bead kit (Beckman Coulter, Brea, CA, USA) and quantified using the Picogreen method (Invitrogen, Carlsbad, CA, USA). Subsequently, the amplicon was diluted and analyzed with a GS-FLX Titanium sequencer (Roche Diagnostics GmbH) at Macrogen (Seoul, Korea).

Phylogenetic classification

Sequencing reads were obtained in high quality as determined by the Quality score (mean Phred score > 20 and read length > 300 bp). The operational taxonomic unit (OTU) was analyzed using UCLUST and USEARCH, with phylogenetic classification performed using QIIME based on the 16sRNA sequence database of GreenGenes 8.15.13. All sequences

were classified based on the similarity as follows: species, > 97% similarity; genus, > 94% similarity; family, > 90% similarity; order, > 85% similarity; class, > 80% similarity; and phylum, > 75% similarity. If there was a significant difference (more than 2-fold difference between the case and control groups) in the bacterial EV composition of the genus level, then the data were configured as a heatmap.

Lactobacillus plantarum-derived EV isolation

We selected *Lactobacillus* in the mouse study because many studies have already confirmed the beneficial effects for eczema of *Lactobacillus*.¹⁸⁻²⁶ Among *Lactobacillus*, the *L. plantarum* (KCTC 11401BP, Gen-Bank accession No. GQ336971) strain was isolated from kimchi, which is the most popular fermented food in Korea and is easily obtained.²⁷ This strain also has the potential to improve mouse and human AD.^{28,29} Finally, we decided to use *L. plantarum* for the experiment, and *L. plantarum* culture medium was donated by Probiotics Research Center, CJ CheilJedang Corporation, Korea. *L. plantarum*-derived EVs (Lp EV) were isolated as EV preparation methods.

Transmission electron microscopy (TEM) image analysis

Purified EVs were diluted to 50 µg/mL with phosphate-buffered saline (PBS), and 10 µL of the EV-suspension were placed on 300-mesh copper grids (EMS, Hatfield, PA, USA) and stained with 2% uranyl acetate on the 300-mesh copper grids. The microscope images were recorded with a JEM1011 electron microscope (JEOL Ltd., Tokyo, Japan).

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis

The protein sample (10 µg) from EVs and whole cell lysate (WCL) were loaded into each well and analyzed with SDS-PAGE (10% resolving gel). The SDS-PAGE gel was stained with CBB R-250 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Dynamic light scattering

The purified EVs were diluted with PBS to 1 µg/mL and measured using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) and Dynamic V6 software³².

In vitro evaluation of immunogenicity

Immortalized human epidermal keratinocytes (HaCaT cells) were donated by Jeung-Hoon Lee (Chungnam National University, Daejeon, Korea). The 2×10^5 HaCaT cells were seeded on 24-well plate in DMEM (Hyclone Laboratories Inc., South Logan, UT, USA) containing 5% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 1% antibiotics (Hyclone Laboratories Inc.). Cells were treated with 0.1, 1 and 10 µg/mL EVs for 12 hours to evaluate the immunogenicity of Lp EVs. After treatment, IL-6 levels in the cultured media were evaluated via enzyme-linked immunosorbent assay (ELISA) following manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).

In vitro protection of Lp EVs from Staphylococcus aureus-derived EVs

The cells were pretreated with Lp EV for 12 hours, followed by stimulation with *S. aureus*-induced EVs (Sa EV) for 12 hours. Co-treatment with Lp EV and Sa EV was performed to compare with the pretreatment group. After treatment, the cultured media was evaluated via ELISA by following manufacturer's instruction (R&D Systems). Some of the wells were treated for 24 hours and viability was measured using thiazolyl blue tetrazolium bromide (MTT; Sigma-Aldrich, St. Louis, MO, USA).

In vivo Lp EV administration on mouse skin inflammation model

Sa EVs were administered to mouse skin 3 times per week for 4 weeks to develop the mouse model for skin inflammation. Before administration of Sa EV, the skin of each mouse was stripped 5 times using Durapore surgical tape (3M Co., St. Paul, MN, USA). Gauze (1 × 1 cm) was placed on the stripped mouse skin, and Sa EV in 100 µL PBS were sprayed onto the gauze, which was fixed to the skin using Tegaderm bio-occlusive tape (3M Co.). The Lp EV was administered orally 12 hours before each Sa EV administration for the Lp EV-treated group.

Measurement of cytokines in the mouse skin inflammation model

Skin tissue from each mouse was sampled to evaluate the production of IL-4 and IL-5 in the mouse model. Skin tissue samples were homogenized in RIPA Buffer (ThermoFisher Scientific, Waltham, MA, USA) and were centrifuged at 10,000 × *g* for 20 minutes at 4°C. The supernatant was collected, and IL-4 and IL-5 levels were determined using ELISA according to the manufacturer's instructions (R&D Systems).

Histological analysis

Isolated skin tissues were fixed in paraffin, sectioned and stained with hematoxylin and eosin (H&E). The skin tissues were analyzed at 200 × magnification.

Statistical analysis

The results of continuous variables are presented as the mean ± standard deviation. Continuous variables were analyzed using Student's *t* test or the Mann-Whitney *U* test, and categorical variables were analyzed using the chi-square test or Fisher's exact test. Statistical significance indicated by a *P* value of < 0.05. SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was used for analyses.

RESULTS

Clinical characteristics of AD patients and normal controls

Twenty-seven AD patients and 6 normal controls were enrolled. The mean ages of the AD patients and controls were 91 and 83 months, respectively. In both AD and control participants, 66.7% were boys. Eosinophil count and ECP were 877.8 cells/µL and 66.4 µg/L, respectively. Specific IgE to any allergen was positive in 26 patients. Among them, 66.7% were positive for the specific IgE for house dust mites. All patients were treated with wet dressings, topical corticosteroids, antihistamines and antibiotics. Topical calcineurin inhibitors and systemic corticosteroids were used in 66.7% and 18.5% of the patients, respectively. The SCORAD index was significantly decreased from 75.5 to 41.4 after treatment (*P* < 0.001). Laboratory tests were not conducted in the normal control group (**Supplementary Table S1**).

Comparison of bacterial EV composition in the urine and serum of the AD patients

Bacterial EV compositions in the urine and serum of the AD patients were compared each other to confirm the similarity of both sample types. The 2 sample types closely resembled each other in 18 AD patients whose serum and urine samples were collected simultaneously (**Supplementary Fig. S1A and B**). As shown in **Supplementary Fig. S1C**, the cluster of samples in blood (in blue) cannot be separated from the cluster of samples in urine (in orange), which implies that the bacterial compositions of the 2 groups are quite similar. This interpretation was confirmed further by the *t* test results with PC1 and PC2 (*P* value > 0.1). After confirming

the similarity of bacterial EV composition in blood and urine by principal component analysis (PCA; **Supplementary Fig. S1C**), we decided to continue the analysis using urine samples, which were easier to collect.

Differences in bacterial EV composition in the urine of the AD patients and normal controls

Bacterial diversity as determined by the Chao 1 index was markedly decreased in AD patients compared to the control group (**Fig. 1A**). Definite separation of bacterial EV composition between AD patients and the control group was observed in PCA (**Fig. 1B**). At the phylum level, Firmicutes was dominant in the controls, and Proteobacteria was dominant in AD patients (**Fig. 1C**). A heatmap of the genus level revealed notable differences in bacterial EV composition in the urine of the control and AD patients (**Figs. 1D and 2A**). The proportions of *Lactococcus*, *Leuconostoc*, *Lactobacillus* and *Lactobacillales(o)* were significantly higher in




Fig. 1. (A) Alpha-diversity as determined by the Chao 1 index. (B) Beta-diversity defined by PCA. (C) Bacterial community analysis of the urine of AD patients and normal controls at the phylum level. (D) Bacterial community analysis of the urine of patients and controls at the genus level (case: AD patients, control: healthy controls). PCA, principal component analysis; AD, atopic dermatitis.

the control group than in the AD patient group, and *Alicyclobacillus*, *Propionibacterium* and *Streptophyta(o)* were more increased in the AD patient group compared with the control group. *Pseudomonas* was common in both groups (**Fig. 2A and B**).

Lactobacillus comprised 20.9% and 4.6% of the total flora in the control and AD patient groups, respectively. Respective values were 18.2% and 0.02% for *Lactobacillales(o)*, 14.6% and 0.1% for *Leuconostoc*, and 11.6% and 0.03% for *Lactococcus*. *Alicyclobacillus* comprised 0.3% and 8.5% of the control and AD patient groups, respectively. Other respective values were 2.9% and 7.9% for *Streptophyta(o)*, and 2.8% and 7.6% for *Propionibacterium* (**Fig. 2B, Supplementary Table S2**).




Fig. 2. (A) Differences in bacterial EVs composition in the urine of AD patients and normal controls. (B) Bacterial community analysis of the urine of AD patients and normal controls at the genus level. EV, extracellular vesicle; AD, atopic dermatitis.

Post-treatment changes in the bacterial EV profile in urine in AD patients

Urine samples were collected before and after treatment from 10 AD patients. Then, we compared the changes in bacterial EVs composition based on the treatment in this group. Before the treatment, *Alicyclobacillus* and *Comamonadaceae(f)* were frequently found in AD patients. These proportions were decreased after treatment, while those of *Acinetobacter* and *Oxalobacteraceae(f)* were increased (**Supplementary Fig. S2A and B**). The proportions of *Alicyclobacillus* and *Comamonadaceae(f)* decreased from 8.7% to 1.9% and from 7.2% to 2.6%, respectively, after the treatment. The proportions of *Acinetobacter* and *Oxalobacteraceae(f)* were increased from 0.6% to 12.4% and from 3.0% to 9.2%, respectively, after the treatment (**Supplementary Table S3**). At the phylum level, Proteobacteria was dominant in both groups, and Firmicutes decreased after treatment. (**Supplementary Fig. S2C**).

Characterization of EVs from Lp EV

The Lp EV were purified according to EV isolation methods used in the previous study.²⁶ First, we analyzed the morphology of EVs using TEM. We observed spherical lipid bi-layer vesicles (**Fig. 3A**). The size distribution of EVs was measured using a dynamic light-scattering analyzer. The diameter of EVs ranged from 20 to 100 nm (**Fig. 3B**). Next, we analyzed the protein patterns of EVs and WCL with SDS-PAGE. The EVs showed distinct protein patterns




Fig. 3. Characterization of EVs from *Lactobacillus plantarum*. (A) TEM images of purified EVs from *L. plantarum*. (B) The size distribution of EVs from *L. plantarum*. The size distribution of EVs was measured in a diameter range of 20 to 50 nm. (C) SDS-PAGE analysis of purified proteins (WCL, EVs) from *L. plantarum*. Standard markers are shown on the left (kDa).

EV, extracellular vesicle; TEM, transmission electron microscopy; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; WCL, whole cell lysate.

compared with WCL (**Fig. 3C**). These results suggest that EVs contain sorted proteins from host cells and that there are sorting mechanisms when EVs are produced.

In vitro effects of Lp EV on the secretion of IL-6 from keratinocytes and macrophages

We assumed that EV from lactic acid bacteria would have some protective or beneficial roles against AD because we found that EVs of the lactobacilli group were dominant in the urine of normal controls compared to that of AD patients. As mentioned above, *L. plantarum* was selected as an experimental material among the lactic acid bacteria because it was easily obtained from kimchi, which is a familiar Korean food. First, we evaluated the therapeutic or preventive effect of EVs from *L. plantarum* on keratinocytes and macrophages. The concentration of the Lp EV used to treat the keratinocytes was determined at a level that did not cause skin irritation or inflammation compared to Sa EV, a positive control, which was already known to cause AD-like skin inflammation (**Fig. 4A**).^{30,31} IL-6 secretion from keratinocyte was decreased with Lp EV treatment prior to Sa EV treatment in a dose-dependent manner, but not in the co-treatment model of Lp EV and Sa EV (**Fig. 4A**). IL-6 secretion from macrophages was also decreased with Lp EV pre-treatment, while no decrease was observed in the co-treatment group (**Supplementary Fig. S3A**). Cell viability was also restored with Lp EV pre-treatment on the keratinocytes (**Fig. 4B**). However, these trends failed to demonstrate statistical significance




Fig. 4. (A) *In vitro* effects of *Lactobacillus plantarum* on the secretion of IL-6 from keratinocytes stimulated by Sa EV. NC was treated only with PBS, and PC was treated only with Sa EV. Pre- and co-treatment indicates that Lp EV was treated before Sa EV stimulation, or at the same time, respectively. (B) Keratinocytes cell viability assessment. IL, interleukin; Sa EV, *Staphylococcus aureus*-induced extracellular vesicle; NC, negative control; PBS, phosphate-buffered saline; PC, positive control; Lp EV, *Lactobacillus plantarum*-derived extracellular vesicle. **P* < 0.05 vs. NC; †*P* < 0.05 vs. PC; ‡*P* < 0.01 vs. PC (Mann-Whitney *U* test).

in macrophages (Supplementary Fig. S3B). These findings suggest that Lp EV could have a preventive effect on skin inflammation.

In vivo effects of oral Lp EV on the AD mouse model induced by Sa EV

In the previous study, we demonstrated that Sa EV causes AD-like skin inflammation which was characterized by epidermal thickening with infiltration of the dermis by mast cells and eosinophils, and cutaneous production of IL-4, IL-5, interferon (IFN)- γ and IL-17.³⁰ Epidermal thickening with the infiltration of inflammatory cells, especially eosinophils and increase in type 2 cytokines has been regarded as AD-like skin inflammation in mouse experiments.^{28,30-32} In the current study, we administered oral Lp EV to the Sa EV-induced AD mouse model to evaluate the *in vivo* effects of Lp EV on AD. Lp EV was administered orally for 25 days together with Sa EV application 3 times a week, and the effect was compared with that of dexamethasone treatment (Fig. 5A). Dexamethasone markedly decreased skin Sa EV-induced skin inflammation (Fig. 5B). Although low-dose Lp EVs (1 μ g) were not effective in improving of skin inflammation, an increased dose reduced skin inflammation and showed




Fig. 5. *In vivo* effects of oral Lp EV on the AD-like skin inflammation. (A) AD mouse model using tape-stripping and Sa EV. (B) Images of H&E-stained skin. (C) Histological analysis of epidermal thickness and infiltrating eosinophil. (D) Levels of IL-4 and IL-5.

Lp EV, *Lactobacillus plantarum*-derived extracellular vesicle; AD, atopic dermatitis; Sa EV, *Staphylococcus aureus*-induced extracellular vesicle; H&E, hematoxylin and eosin; IL, interleukin; NC, negative control; PC, positive control.

* $P < 0.05$ vs. NC; [†] $P < 0.05$ vs. PC; [‡] $P < 0.01$ vs. PC (Mann-Whitney *U* test).

(continued to the next page)




Fig. 5. (Continued) *In vivo* effects of oral Lp EV on the AD-like skin inflammation. (A) AD mouse model using tape-stripping and Sa EV. (B) Images of H&E-stained skin. (C) Histological analysis of epidermal thickness and infiltrating eosinophil. (D) Levels of IL-4 and IL-5. Lp EV, *Lactobacillus plantarum*-derived extracellular vesicle; AD, atopic dermatitis; Sa EV, *Staphylococcus aureus*-induced extracellular vesicle; H&E, hematoxylin and eosin; IL, interleukin; NC, negative control; PC, positive control. * $P < 0.05$ vs. NC; [†] $P < 0.05$ vs. PC; [‡] $P < 0.01$ vs. PC (Mann-Whitney *U* test).

an effect similar to the dexamethasone treatment (**Fig. 5B**). Histological analysis elucidated that eosinophilic inflammation and epidermal thickening were reduced after dexamethasone treatment. Lp EV administration also reduced epidermal thickening, but not eosinophilic infiltration (**Fig. 5C**). Elevated IL-4 levels in the positive control were significantly decreased with Lp EV administration (**Fig. 5D**). These results show that Lp EV may decrease skin inflammation by reducing IL-4 cytokine in a dose-dependent manner.

DISCUSSION

The present study is the first comprehensive analysis of bacterial EV compositions undertaken to reveal the systemic proportion of bacterial EV in AD patients. *Alicyclobacillus*, *Propionibacterium* and *Streptophyta(o)* were increased in AD patients, and *Lactococcus*, *Leuconostoc* and *Lactobacillus* were significantly higher in the control group than in the AD patient group. These data indicate that a deficiency in systemic beneficial bacteria may promote development of AD. In AD patients, *Alicyclobacillus* and *Comamonadaceae(f)* were more frequent in urine before treatment, and *Acinetobacter* and *Oxalobacteraceae(f)* were more frequent after treatment. Then, we used *L. plantarum* to confirm the beneficial effects of lactic acid bacteria. *In vitro* examinations confirmed the anti-inflammatory effects of Lp EVs and their ability to prevent cell death. *In vivo*, Lp EV decreased epidermal thickening and IL-4 levels in the *S. aureus* EV-induced AD model. These findings suggest that Lp EV could have a preventive effect on skin inflammation.

Examinations of urine and blood samples involved detection of bacterial nano-vesicles, not the bacteria themselves. While bacteria might not be widely disseminated in the body, nano-vesicles derived from bacteria can be absorbed and move freely throughout the body.^{12,33} Detection of bacteria-derived vesicles enabled analysis of systemic bacterial effects in humans for the first time. Recent data revealed microbiomes in organs or specimens that were considered sterile in the past. The microbiomes detected in the lungs or in urine are representative examples.^{942,34} Interestingly, there were notable differences in bacterial composition between urine in this study and skin in the previous study.³⁵ *Staphylococcus* was found most commonly in the skin washing fluid of AD patients in our previous study.³⁵ In contrast, *Staphylococcus* was not detected, and *Alicyclobacillus*, *Streptophyta(o)* and *Propionibacterium* were commonly found in the urine of AD patients. The bacterial community might be different between skin and systemic organ, even though *Staphylococcus* is the most common bacteria in the skin, their EV might not be absorbed systemically.

The EV of *Propionibacteria*, which was frequently observed in the urine of AD patients in this study, is not well known for its role in AD even though *Propionibacteria* is normal flora and is one of the most common skin colonizing bacteria.^{36,37} Appropriate culture conditions are not yet established because this bacterium grows very slowly and is difficult to culture.³⁸ Therefore, current culture methods are inappropriate to prove the relationship between *Propionibacterium* and AD. The present metagenomic results linking non-culturable bacteria with AD are important. *Propionibacterium* produces propionic acids and bacteriocin, which prevent proliferation of *S. aureus* or other pathogens. Therefore, it could play an opposing role relative to *S. aureus*.³⁶ Therefore, *Propionibacterium* can be increased to counteract *S. aureus* in AD patients. *Acinetobacter* species are also known for their allergy-protective roles including those against asthma and AD.³⁹⁻⁴¹ This is consistent with our findings that an increased portion of *Acinetobacter* after the treatment of AD showed an inverse relationship with AD. In contrast, EVs of *Pseudomonas* may be commonly observed in the urine of both groups because they are part of the normal flora.⁴²

There have been many studies about the beneficial effects of *Lactococcus* and *Lactobacillus* against allergic diseases.^{21-26,43,44} *Leuconostoc* has not been studied frequently, but one study revealed that it can modulate IgE production in a mouse model with an ovalbumin-induced allergy.⁴⁵ This result matches our observation that lactic acid bacteria were significantly higher in the urine of healthy controls than those of AD patients and showed protective effects both *in vitro* and *in vivo*. *Leuconostoc* has not been studied previously as a part of human microbiome in allergic diseases and our study is the first report of *Leuconostoc* in AD patients. Furthermore, we showed that not only bacteria itself, but also EVs from lactic acid bacteria might have the beneficial effects for AD.

However, the presence of other bacterial EVs in urine such as from *Alicyclobacillus*, *Streptophyta(o)*, *Comamonadaceae(f)* and *Oxalobacteraceae(f)* needs to be studied further in order to determine their role and origin because there is little information about the EVs from these species. Our previous study revealed that Sa EV causes AD-like skin inflammation, and a successive study also showed that α -hemolysin in Sa EV plays an important role in inducing AD-like skin inflammation.^{46,47} These studies strongly suggest a correlation between development of AD and bacteria-derived EV. Another study by the same research group showed that the degree of sensitization to the EV of dust is a risk factor for asthma, chronic obstructive pulmonary disease (COPD) and lung cancer.⁴⁸ EVs might be involved in allergic

inflammatory reactions of the lungs as well as skin. While there are relatively many studies on the relationship between allergic diseases and bacteria, few studies on EV derived from bacteria have been conducted. Therefore, further studies are needed in the future on allergic diseases and bacteria-derived EV.

There are some limitations in this study. First, the number of subjects is small, they are not representatives and the results cannot be applied to the general population. To generalize these results, large-scale studies and sample collection are essential. Secondly, it is still unclear whether lactic acid bacteria have any benefits to humans because we did not perform clinical trials. Their safety and efficacy should be evaluated to apply the treatment to human beings in the future. Thirdly, because AD patients in this study were treated with antibiotics when aggravated, the effects of antibiotics on the microbiome milieu should be considered when interpreting the differences after treatment.

Despite these limitations, our study is a breakthrough study in the bacterial EV composition analysis of AD patients. We analyzed the systemic bacterial composition through the study of nano-vesicles from bacteria and confirmed microbiome milieu by metagenomic analysis, which allowed a broader study of the whole bacterial community. Based on the culture technique to identify the bacteria, only 1% of the entire bacteria could be identified.⁴⁹ Because metagenomic analysis provides much more information compared with a conventional culture technique, it is an essential method in the understanding of bacteria and human diseases.

In this study, we suggested the role of probiotics in the protection against AD. We also established the existence of novel bacterial EV in the urine reflecting a systemic microbiome milieu. Additional studies of microbiome might enable us to differentiate, diagnose and predict the prognosis of AD using microbiome information by local and systemic bacterial composition analyses. Furthermore, we might be able to prevent or treat AD using EVs from probiotics in the near future.

ACKNOWLEDGMENTS

Lactobacillus plantarum culture medium was donated by CJ R&D Center, CJ CheilJedang Corporation. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI13C0040), the Bio & Medical Technology Development Program of the National Research Foundation (NRF) of Korea funded by the Korean government, MSIP (NRF-2016M3A9B6901511, NRF-2014R1A1A1005144), and the Soonchunhyang University Research Fund.

SUPPLEMENTARY MATERIALS

Supplementary Table S1

Clinical characteristics of the study subjects

[Click here to view](#)

Supplementary Table S2

Differences in bacterial EVs composition in the urine of AD patients and NCs

[Click here to view](#)

Supplementary Table S3

Changes in the bacterial proportions in the urine of patients with AD before and after treatment

[Click here to view](#)

Supplementary Fig. S1

(A) Comparison of bacterial EVs composition in the urine and serum of AD patients according to the phylogenetic levels. (B) Comparison of bacterial EVs composition in the urine and serum of AD patients at the genus level. (C) PCA showed a correlation of bacterial composition between urine and serum of AD patients.

[Click here to view](#)

Supplementary Fig. S2

(A) Changes in the bacterial proportions in the urine of patients with AD before and after treatment. (B) Bacterial community analysis of the urine of AD patients before and after treatment at the genus level. (C) Bacterial community analysis of the urine of AD patients before and after treatment according to the phylogenetic hierarchy.

[Click here to view](#)

Supplementary Fig. S3

In vitro effects of *Lactobacillus plantarum* on the secretion of IL-6 from macrophage stimulated by Sa EV.

[Click here to view](#)

Supplementary Fig. S4

In vivo effects of oral Lp EV on AD-like skin inflammation.

[Click here to view](#)

REFERENCES

1. Sabin BR, Peters N, Peters AT. Chapter 20: atopic dermatitis. *Allergy Asthma Proc* 2012;33 Suppl 1:67-9. [PUBMED](#) | [CROSSREF](#)
2. Bieber T. Atopic dermatitis. *N Engl J Med* 2008;358:1483-94. [PUBMED](#) | [CROSSREF](#)
3. Pyun BY. Natural history and risk factors of atopic dermatitis in children. *Allergy Asthma Immunol Res* 2015;7:101-5. [PUBMED](#) | [CROSSREF](#)
4. Ahn K. The prevalence of atopic dermatitis in Korean children. *Allergy Asthma Immunol Res* 2016;8:1-2. [PUBMED](#) | [CROSSREF](#)

5. Hong SJ, Ahn KM, Lee SY, Kim KE. The prevalences of asthma and allergic diseases in Korean children. *Korean J Pediatr* 2008;51:343-50.
[CROSSREF](#)
6. Lee JH, Han KD, Kim KM, Park YG, Lee JY, Park YM. Prevalence of atopic dermatitis in Korean children based on data from the 2008–2011 Korean National Health and Nutrition Examination Survey. *Allergy Asthma Immunol Res* 2016;8:79-83.
[PUBMED](#) | [CROSSREF](#)
7. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *J Clin Invest* 2004;113:651-7.
[PUBMED](#) | [CROSSREF](#)
8. Boguniewicz M, Leung DY. 10. Atopic dermatitis. *J Allergy Clin Immunol* 2006;117:S475-80.
[PUBMED](#) | [CROSSREF](#)
9. Jang SC, Kim SR, Yoon YJ, Park KS, Kim JH, Lee J, et al. *In vivo* kinetic biodistribution of nano-sized outer membrane vesicles derived from bacteria. *Small* 2015;11:456-61.
[PUBMED](#) | [CROSSREF](#)
10. Kim JH, Lee J, Park J, Gho YS. Gram-negative and gram-positive bacterial extracellular vesicles. *Semin Cell Dev Biol* 2015;40:97-104.
[PUBMED](#) | [CROSSREF](#)
11. Shin TS, Kim JH, Kim YS, Jeon SG, Zhu Z, Gho YS, et al. Extracellular vesicles are key intercellular mediators in the development of immune dysfunction to allergens in the airways. *Allergy* 2010;65:1256-65.
[PUBMED](#) | [CROSSREF](#)
12. Admyre C, Telemo E, Almqvist N, Lötval J, Laheesmaa R, Scheynius A, et al. Exosomes - nanovesicles with possible roles in allergic inflammation. *Allergy* 2008;63:404-8.
[PUBMED](#) | [CROSSREF](#)
13. Mathieu A, Vogel TM, Simonet P. The future of skin metagenomics. *Res Microbiol* 2014;165:69-76.
[PUBMED](#) | [CROSSREF](#)
14. Eisen JA. Environmental shotgun sequencing: its potential and challenges for studying the hidden world of microbes. *PLoS Biol* 2007;5:e82.
[PUBMED](#) | [CROSSREF](#)
15. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol* 1980;60 Suppl 92:44-7.
16. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. *Dermatology* 1993;186:23-31.
[PUBMED](#) | [CROSSREF](#)
17. Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. Gram-positive bacteria produce membrane vesicles: proteomics-based characterization of *Staphylococcus aureus*-derived membrane vesicles. *Proteomics* 2009;9:5425-36.
[PUBMED](#) | [CROSSREF](#)
18. Vitaliti G, Pavone P, Guglielmo F, Spataro G, Falsaperla R. The immunomodulatory effect of probiotics beyond atopy: an update. *J Asthma* 2014;51:320-32.
[PUBMED](#) | [CROSSREF](#)
19. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. *Clin Diagn Lab Immunol* 2001;8:695-701.
[PUBMED](#)
20. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells *in vitro* by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol* 2005;115:1260-7.
[PUBMED](#) | [CROSSREF](#)
21. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003;111:389-95.
[PUBMED](#) | [CROSSREF](#)
22. West CE, Hammarström ML, Hernell O. Probiotics in primary prevention of allergic disease--follow-up at 8–9 years of age. *Allergy* 2013;68:1015-20.
[PUBMED](#) | [CROSSREF](#)
23. Yang HJ, Min TK, Lee HW, Pyun BY. Efficacy of probiotic therapy on atopic dermatitis in children: a randomized, double-blind, placebo-controlled trial. *Allergy Asthma Immunol Res* 2014;6:208-15.
[PUBMED](#) | [CROSSREF](#)

24. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. *Cochrane Database Syst Rev* 2007:CD006475.
[PUBMED](#) | [CROSSREF](#)
25. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. *Cochrane Database Syst Rev* 2008:CD006135.
[PUBMED](#)
26. Niccoli AA, Artesi AL, Candio F, Ceccarelli S, Cozzali R, Ferraro L, et al. Preliminary results on clinical effects of probiotic *Lactobacillus salivarius* LS01 in children affected by atopic dermatitis. *J Clin Gastroenterol* 2014;48 Suppl 1:S34-6.
[PUBMED](#) | [CROSSREF](#)
27. Won TJ, Kim B, Lee Y, Bang JS, Oh ES, Yoo JS, et al. Therapeutic potential of *Lactobacillus plantarum* CJLP133 for house-dust mite-induced dermatitis in NC/Nga mice. *Cell Immunol* 2012;277:49-57.
[PUBMED](#) | [CROSSREF](#)
28. Won TJ, Kim B, Lim YT, Song DS, Park SY, Park ES, et al. Oral administration of *Lactobacillus* strains from kimchi inhibits atopic dermatitis in NC/Nga mice. *J Appl Microbiol* 2011;110:1195-202.
[PUBMED](#) | [CROSSREF](#)
29. Han Y, Kim B, Ban J, Lee J, Kim BJ, Choi BS, et al. A randomized trial of *Lactobacillus plantarum* CJLP133 for the treatment of atopic dermatitis. *Pediatr Allergy Immunol* 2012;23:667-73.
[PUBMED](#) | [CROSSREF](#)
30. Yamamoto M, Haruna T, Yasui K, Takahashi H, Iduhara M, Takaki S, et al. A novel atopic dermatitis model induced by topical application with *Dermatophagoides farinae* extract in NC/Nga mice. *Allergol Int* 2007;56:139-48.
[PUBMED](#) | [CROSSREF](#)
31. Kim H, Kim HR, Kim NR, Jeong BJ, Lee JS, Jang S, et al. Oral administration of *Lactobacillus plantarum* lysates attenuates the development of atopic dermatitis lesions in mouse models. *J Microbiol* 2015;53:47-52.
[PUBMED](#) | [CROSSREF](#)
32. Jeong YI, Hong SH, Cho SH, Lee WJ, Lee SE. *Toxoplasma gondii* infection suppresses house dust mite extract-induced atopic dermatitis in NC/Nga mice. *Allergy Asthma Immunol Res* 2015;7:557-64.
[PUBMED](#) | [CROSSREF](#)
33. Pyun BY. Extracellular vesicle: an unknown environmental factor for causing airway disease. *Allergy Asthma Immunol Res* 2016;8:179-80.
[PUBMED](#) | [CROSSREF](#)
34. Choi Y, Park H, Park HS, Kim YK. Extracellular vesicles, a key mediator to link environmental microbiota to airway immunity. *Allergy Asthma Immunol Res* 2017;9:101-6.
[PUBMED](#) | [CROSSREF](#)
35. Kim MH, Rho M, Choi JP, Choi HI, Park HK, Song WJ, et al. A metagenomic analysis provides a culture-independent pathogen detection for atopic dermatitis. *Allergy Asthma Immunol Res* 2017;9:453-61.
[PUBMED](#) | [CROSSREF](#)
36. Findley K, Grice EA. The skin microbiome: a focus on pathogens and their association with skin disease. *PLoS Pathog* 2014;10:e1004436.
[PUBMED](#) | [CROSSREF](#)
37. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. *Science* 2009;324:1190-2.
[PUBMED](#) | [CROSSREF](#)
38. Butler-Wu SM, Burns EM, Pottinger PS, Magaret AS, Rakeman JL, Matsen FA 3rd, et al. Optimization of periprosthetic culture for diagnosis of *Propionibacterium acnes* prosthetic joint infection. *J Clin Microbiol* 2011;49:2490-5.
[PUBMED](#) | [CROSSREF](#)
39. Ege MJ, Mayer M, Schwaiger K, Mattes J, Pershagen G, van Hage M, et al. Environmental bacteria and childhood asthma. *Allergy* 2012;67:1565-71.
[PUBMED](#)
40. Fyhrquist N, Ruokolainen L, Suomalainen A, Lehtimäki S, Veckman V, Vendelin J, et al. *Acinetobacter* species in the skin microbiota protect against allergic sensitization and inflammation. *J Allergy Clin Immunol* 2014;134:1301-1309.e11.
[PUBMED](#) | [CROSSREF](#)
41. Brand S, Teich R, Dicke T, Harb H, Yildirim AO, Tost J, et al. Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by microbes. *J Allergy Clin Immunol* 2011;128:618-625.e1-7.
[PUBMED](#) | [CROSSREF](#)

42. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? *Br J Dermatol* 2008;158:442-55.
[PUBMED](#) | [CROSSREF](#)
43. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live *Lactobacillus reuteri* inhibits the allergic airway response in mice. *Am J Respir Crit Care Med* 2007;175:561-9.
[PUBMED](#) | [CROSSREF](#)
44. Sjögren YM, Jenmalm MC, Böttcher MF, Björkstén B, Sverremark-Ekström E. Altered early infant gut microbiota in children developing allergy up to 5 years of age. *Clin Exp Allergy* 2009;39:518-26.
[PUBMED](#) | [CROSSREF](#)
45. Kang H, Oh YJ, Ahn KS, Eom HJ, Han N, Kim YB, et al. *Leuconostoc citreum* HJ-P4 (KACC 91035) regulates immunoglobulin E in an ovalbumin-induced allergy model and induces interleukin-12 through nuclear factor-kappa B and p38/c-Jun N-terminal kinases signaling in macrophages. *Microbiol Immunol* 2009;53:331-9.
[PUBMED](#) | [CROSSREF](#)
46. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. Extracellular vesicles derived from *Staphylococcus aureus* induce atopic dermatitis-like skin inflammation. *Allergy* 2011;66:351-9.
[PUBMED](#) | [CROSSREF](#)
47. Hong SW, Choi EB, Min TK, Kim JH, Kim MH, Jeon SG, et al. An important role of α -hemolysin in extracellular vesicles on the development of atopic dermatitis induced by *Staphylococcus aureus*. *PLoS One* 2014;9:e100499.
[PUBMED](#) | [CROSSREF](#)
48. Kim YS, Choi JP, Kim MH, Park HK, Yang S, Kim YS, et al. IgG sensitization to extracellular vesicles in indoor dust is closely associated with the prevalence of non-eosinophilic asthma, COPD, and lung cancer. *Allergy Asthma Immunol Res* 2016;8:198-205.
[PUBMED](#) | [CROSSREF](#)
49. Grice EA, Kong HH, Renaud G, Young AC, NISC Comparative Sequencing Program Bouffard GG, et al. A diversity profile of the human skin microbiota. *Genome Res* 2008;18:1043-50.
[PUBMED](#) | [CROSSREF](#)